A district court judge invents strict scrutiny requirement for commercial speech.
The FDA’s proposal to modernize generic drug approvals meets with broad support.
New bill would allow manufacturers of certain medical device to bypass elements of FDA’s existing process.
President’s advisers signal willingness to “work with religious groups.”
Agency recommends statutory language for imposing user fees on biosimilar drug manufacturers.
The FDA cautions patients to undergo only approved stem cell treatments.
Regulatory conference highlights need for defined governance of laboratory developed diagnostic testing.
Health care reform, the Dodd-Frank Act, environmental protection, and open government are discussed in our top news posts from 2011.
Legislation seeks to speed FDA review of medical products.
Governmental and nongovernmental action taken to discourage illegal pharmaceutical sales over the Internet.
“Network of Experts” intended to give FDA quicker information on emerging medical devices.
Agency intends to prohibit the sale of synthetic stimulants, at least temporarily.